首页> 美国卫生研究院文献>Therapeutic Advances in Gastroenterology >SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

【2h】

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

机译：SB5对阿达木单抗具有交叉免疫原性但对英夫利昔单抗不具有交叉免疫原性：导致炎症性肠病或类风湿关节炎的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA).

机译：这项研究的主要目的是分析炎症性肠病（IBD）或类风湿关节炎（RA）患者中抗药物抗体与参考阿达木单抗（ADL）和SB5（阿达木单抗类似物）的交叉反应性。

著录项

期刊名称 Therapeutic Advances in Gastroenterology
作者
Joao Goncalves; Gihyun Myung; MinJeong Park; Deokyoon Jeong; Jeehoon Ghil;
展开▼
作者单位

展开▼
年(卷),期 2019(12),-1
年度 2019
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词
anti-TNF; biologic therapies; biosimilar; adalimumab; inflammatory bowel disease;

机译：抗TNF;生物疗法;生物仿制药;阿达木单抗;炎症性肠病;

相似文献

外文文献
中文文献
专利

1. SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis [J] . Joao Goncalves, Gihyun Myung, MinJeong Park, Therapeutic advances in gastroenterology. . 2019,第12期

机译：SB5显示了对Adalimalab的交叉免疫原性，但不是英夫利昔单抗：导致炎症肠道疾病或类风湿性关节炎的患者
2. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis [J] . Weinblatt Michael E., Baranauskaite Asta, Dokoupilova Eva, Arthritis & rheumatology. . 2018,第6期

机译：在类风湿性关节炎患者中从参考AdaTimalab转换为SB5（Adalimalab BioSimilar）
3. Impact of Anti-Drug Antibodies on Efficacy and Safety up to Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimilar) with Reference Adalimumab in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy [J] . Genovese Mark, Weinblatt Michael, Keystone Edward, The Journal of rheumatology . 2017,第6期

机译：尽管甲氨蝶呤治疗，抗药物抗体对比较SB5（Adalimalab BioSimilar）与参考患者的疗效和安全性的影响，从A III阶段研究比较SB5
4. Human Antichimeric Antibodies to Infliximab and Infusion-Related Allergic Reactions in Patients with Rheumatoid Arthritis [C] . D. Wouters, S. Stapel, M. Vis, Collegium Internationale Allergologicum . 2007

机译：人的苯甲酸纤维化率和类风湿性关节炎患者的infumency相关过敏反应的抗体抗体
5. Serum and Fecal Biomarkers Predict Response to Infliximab Therapy in Pediatric Patients with Inflammatory Bowel Disease [D] . Kim, Jochebed. 2020

机译：血清和粪便生物标志物预测对炎症肠病小儿患者的英夫利昔单抗疗法的反应
6. Phase III Randomized Study of SB5 an Adalimumab Biosimilar Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis [O] . Michael E. Weinblatt, Asta Baranauskaite, Jaroslaw Niebrzydowski, -1

机译：中度至重度类风湿关节炎患者SB5（一种Adalimumab生物仿制药与参考Adalimumab相比）的III期随机研究
7. P664 SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis [O] . J Gonçalves, G Myung, E Hong, 2019

机译：P664 SB5和参考Adalimumab显示炎症性肠病或类风湿性关节炎患者的交叉免疫原性

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

摘要

著录项

相似文献

相关主题

期刊订阅